Seki, Noriyasu http://orcid.org/0000-0001-7118-8926
Tsujimoto, Hideto
Tanemura, Shuhei
Kojima, Shinji
Miyoshi, Fumihiko
Kikuchi, Jun http://orcid.org/0000-0003-3231-8841
Saito, Shuntaro
Akiyama, Mitsuhiro
Sugahara, Kunio
Yoshimoto, Keiko
Kaneko, Yuko
Chiba, Kenji http://orcid.org/0000-0002-1687-1746
Takeuchi, Tsutomu http://orcid.org/0000-0003-1111-8218
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
Article History
Received: 28 August 2023
Accepted: 28 February 2024
First Online: 6 March 2024
Competing interests
: The authors declare the following competing interests: Y.K. has received speaking or consultant fees from Asahikasei Pharma Corp. and Eli Lilly Japan KK. T.T. has received speaking or consultant fees from AbbVie GK, Bristol-Myers KK, and Chugai Pharmaceutical Co., Ltd. All other authors declare no competing interests.